Journal of Biological Chemistry · 2009 · 69 citations · 22 references
Life SciencesBiochemistryMicrobiologyAntimicrobial ResistanceEnzymologyMicrobial MetabolismAntibacterial ResistanceAntibiotic ResistanceAntibiotic Resistance MechanismsBacterial MetabolismCarbapenem ResistanceEnzyme KineticsAmino Acid SubstitutionAmino Acid Substitution EffectsCarbapenem AntibioticsCatalytic AcylationExtended-spectrum Beta-lactamase-producing OrganismsPre-steady-state KineticsRate-determining StepSteady-state Kinetics
A major mechanism of bacterial resistance to β-lactam antibiotics (penicillins, cephalosporins, carbapenems, etc.) is the production of β-lactamases. A handful of class A β-lactamases have been discovered that have acquired the ability to turn over carbapenem antibiotics. This is a disconcerting development, as carbapenems are often considered last resort antibiotics in the treatment of difficult infections. The GES family of β-lactamases constitutes a group of extended spectrum resistance enzymes that hydrolyze penicillins and cephalosporins avidly. A single amino acid substitution at position 170 has expanded the breadth of activity to include carbapenems. The basis for this expansion of activity is investigated in this first report of detailed steady-state and pre-steady-state kinetics of carbapenem hydrolysis, performed with a class A carbapenemase. Monitoring the turnover of imipenem (a carbapenem) by GES-1 (Gly-170) revealed the acylation step as rate-limiting. GES-2 (Asn-170) has an enhanced rate of acylation, compared with GES-1, and no longer has a single rate-determining step. Both the acylation and deacylation steps are of equal magnitude. GES-5 (Ser-170) exhibits an enhancement of the rate constant for acylation by a remarkable 5000-fold, whereby the enzyme acylation event is no longer rate-limiting. This carbapenemase exhibits kcat/Km of 3 × 105 m−1s−1, which is sufficient for manifestation of resistance against imipenem. A major mechanism of bacterial resistance to β-lactam antibiotics (penicillins, cephalosporins, carbapenems, etc.) is the production of β-lactamases. A handful of class A β-lactamases have been discovered that have acquired the ability to turn over carbapenem antibiotics. This is a disconcerting development, as carbapenems are often considered last resort antibiotics in the treatment of difficult infections. The GES family of β-lactamases constitutes a group of extended spectrum resistance enzymes that hydrolyze penicillins and cephalosporins avidly. A single amino acid substitution at position 170 has expanded the breadth of activity to include carbapenems. The basis for this expansion of activity is investigated in this first report of detailed steady-state and pre-steady-state kinetics of carbapenem hydrolysis, performed with a class A carbapenemase. Monitoring the turnover of imipenem (a carbapenem) by GES-1 (Gly-170) revealed the acylation step as rate-limiting. GES-2 (Asn-170) has an enhanced rate of acylation, compared with GES-1, and no longer has a single rate-determining step. Both the acylation and deacylation steps are of equal magnitude. GES-5 (Ser-170) exhibits an enhancement of the rate constant for acylation by a remarkable 5000-fold, whereby the enzyme acylation event is no longer rate-limiting. This carbapenemase exhibits kcat/Km of 3 × 105 m−1s−1, which is sufficient for manifestation of resistance against imipenem. Bacterial production of β-lactamases is a primary mechanism of resistance to β-lactam antibiotics (1Fisher J.F. Meroueh S.O. Mobashery S. Chem. Rev. 2005; 105: 395-424Crossref PubMed Scopus (760) Google Scholar). These enzymes hydrolytically process the β-lactam bond of the antibiotic, and by so doing, inactivate them. Four classes of β-lactamases, A, B, C, and D, are known, of which the class A enzymes are most prevalent (1Fisher J.F. Meroueh S.O. Mobashery S. Chem. Rev. 2005; 105: 395-424Crossref PubMed Scopus (760) Google Scholar, 2Babic M. Hujer A.M. Bonomo R.A. Drug Resist. Updat. 2006; 9: 142-156Crossref PubMed Scopus (152) Google Scholar). Enzymes belonging to classes A, C, and D are serine-dependent. A critical active site serine in these enzymes experiences acylation by the antibiotic followed by deacylation. The mechanistic details of the deacylation steps vary for each class (1Fisher J.F. Meroueh S.O. Mobashery S. Chem. Rev. 2005; 105: 395-424Crossref PubMed Scopus (760) Google Scholar). Class B enzymes are zinc-dependent, and their mechanistic details are distinct. Random mutations in the genes for these enzymes have allowed for selection of novel variants within the clinic having an increased breadth for substrate preference (3Walther-Rasmussen J. Høiby N. J. Antimicrob. Chemother. 2007; 60: 470-482Crossref PubMed Scopus (215) Google Scholar). Variants of β-lactamases with the ability to turn over both penicillins and cephalosporins are referred to as extended spectrum β-lactamases (4Page M.G. Clin. Microbiol. Infect. 2008; 14: 63-74Abstract Full Text Full Text PDF PubMed Scopus (37) Google Scholar). Extended spectrum β-lactamases typically do not have the ability to hydrolyze carbapenems; however, exceptions to this rule are emerging among members of classes A, B, and D and are called carbapenemases (5Queenan A.M. Bush K. Clin. Microbiol. Rev. 2007; 20: 440-458Crossref PubMed Scopus (1863) Google Scholar, 6Nordmann P. Poirel L. Clin. Microbiol. Infect. 2002; 8: 321-331Abstract Full Text Full Text PDF PubMed Scopus (595) Google Scholar). Within class A, members of the KPC and GES families are becoming increasingly problematic within the clinic (3Walther-Rasmussen J. Høiby N. J. Antimicrob. Chemother. 2007; 60: 470-482Crossref PubMed Scopus (215) Google Scholar, 5Queenan A.M. Bush K. Clin. Microbiol. Rev. 2007; 20: 440-458Crossref PubMed Scopus (1863) Google Scholar, 7Nordmann P. Cuzon G. Naas T. Lancet Infect. Dis. 2009; 9: 228-236Abstract Full Text Full Text PDF PubMed Scopus (1200) Google Scholar). The GES type class A β-lactamases were identified for the first time only 10 years ago, but they have been increasingly detected worldwide among Gram-negative bacteria (3Walther-Rasmussen J. Høiby N. J. Antimicrob. Chemother. 2007; 60: 470-482Crossref PubMed Scopus (215) Google Scholar). The first variants detected were plasmid borne and isolated from Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, and Enterobacter cloacae (8Bae I.K. Lee Y.N. Jeong S.H. Hong S.G. Lee J.H. Lee S.H. Kim H.J. Youn H. Diagn. Microbiol. Infect. Dis. 2007; 58: 465-468Crossref PubMed Scopus (49) Google Scholar, 9Vourli S. Giakkoupi P. Miriagou V. Tzelepi E. Vatopoulos A.C. Tzouvelekis L.S. FEMS Microbiol. Lett. 2004; 234: 209-213PubMed Google Scholar, 10Poirel L. Le Thomas I. Naas T. Karim A. Nordmann P. Antimicrob. Agents Chemother. 2000; 44: 622-632Crossref PubMed Scopus (367) Google Scholar, 11Poirel L. Weldhagen G.F. Naas T. De Champs C. Dove M.G. Nordmann P. Antimicrob. Agents Chemother. 2001; 45: 2598-2603Crossref PubMed Scopus (194) Google Scholar, 12Giakkoupi P. Tzouvelekis L.S. Tsakris A. Loukova V. Sofianou D. Tzelepi E. Antimicrob. Agents Chemother. 2000; 44: 2247-2253Crossref PubMed Scopus (93) Google Scholar, 13Wachino J. Doi Y. Yamane K. Shibata N. Yagi T. Kubota T. Arakawa Y. Antimicrob. Agents Chemother. 2004; 48: 2905-2910Crossref PubMed Scopus (65) Google Scholar, 14Wachino J. Doi Y. Yamane K. Shibata N. Yagi T. Kubota T. Ito H. Arakawa Y. Antimicrob. Agents Chemother. 2004; 48: 1960-1967Crossref PubMed Scopus (64) Google Scholar); however, newer variants have been identified in the chromosome of P. aeruginosa (15Poirel L. Brinas L. Fortineau N. Nordmann P. Antimicrob. Agents Chemother. 2005; 49: 3593-3597Crossref PubMed Scopus (65) Google Scholar, 16Mavroidi A. Tzelepi E. Tsakris A. Miriagou V. Sofianou D. Tzouvelekis L.S. J. Antimicrob. Chemother. 2001; 48: 627-630Crossref PubMed Google Scholar). A distinguishing characteristic of this family of enzymes is its ability to develop resistance to all classes of β-lactam antibiotics, including third-generation cephalosporins, cephamycins, monobactams, and/or carbapenems. This is in stark contrast to “classical” β-lactamases, such as the TEM family of enzymes, which also rapidly evolved to produce numerous extended spectrum and inhibitor-resistant variants, yet have failed to evolve activity against carbapenem antibiotics. This combination of resistance to both extended spectrum β-lactams and carbapenem antibiotics makes the organisms that harbor the genes for these enzymes dangerous in a clinical setting as treatment options dwindle. GES-1, the first member of the GES family to be identified, has no significant ability to hydrolyze carbapenems, leading to its classification as only an extended spectrum β-lactamase (10Poirel L. Le Thomas I. Naas T. Karim A. Nordmann P. Antimicrob. Agents Chemother. 2000; 44: 622-632Crossref PubMed Scopus (367) Google Scholar). Other GES-type enzymes were later discovered with increased resistance to carbapenems. Two of these variants, GES-2 and -5, contain only a single amino acid substitution compared with the sequence of GES-1, both at position 170 (Ambler numbering is used) (17Ambler R.P. Coulson A.F. Frère J.M. Ghuysen J.M. Joris B. Forsman M. Levesque R.C. Tiraby G. Waley S.G. Biochem. J. 1991; 276: 269-270Crossref PubMed Scopus (862) Google Scholar). This position is located within an Ω-loop forming one of the walls of the active site (1Fisher J.F. Meroueh S.O. Mobashery S. Chem. Rev. 2005; 105: 395-424Crossref PubMed Scopus (760) Google Scholar). The canonical residue at this position of class A β-lactamases is asparagine, which is found in GES-2. However, GES-1 contains a glycine, and GES-5 contains a serine (17Ambler R.P. Coulson A.F. Frère J.M. Ghuysen J.M. Joris B. Forsman M. Levesque R.C. Tiraby G. Waley S.G. Biochem. J. 1991; 276: 269-270Crossref PubMed Scopus (862) Google Scholar). We recently solved the x-ray crystal structure of the GES-1 enzyme; however, it was not clear from the structural data why such a substitution would convey resistance in GES-2 and -5, in contrast to the case of GES-1, which does not (18Smith C.A. Caccamo M. Kantardjieff K.A. Vakulenko S. Acta Crystallogr. D Biol. Crystallogr. 2007; 63: 982-992Crossref PubMed Scopus (33) Google Scholar). The mechanistic basis for the extended profile for resistance is not known, and it is the subject of study in this report. Previous kinetic analyses of class A carbapenemases, including GES enzymes, have been limited to steady-state kinetic parameters (8Bae I.K. Lee Y.N. Jeong S.H. Hong S.G. Lee J.H. Lee S.H. Kim H.J. Youn H. Diagn. Microbiol. Infect. Dis. 2007; 58: 465-468Crossref PubMed Scopus (49) Google Scholar, 10Poirel L. Le Thomas I. Naas T. Karim A. Nordmann P. Antimicrob. Agents Chemother. 2000; 44: 622-632Crossref PubMed Scopus (367) Google Scholar, 11Poirel L. Weldhagen G.F. Naas T. De Champs C. Dove M.G. Nordmann P. Antimicrob. Agents Chemother. 2001; 45: 2598-2603Crossref PubMed Scopus (194) Google Scholar). In this report, we have performed an in-depth analysis of the GES family, including both steady-state and the first pre-steady-state analyses (for any class A carbapenemase) to elucidate the nature of the microscopic steps (binding, acylation, deacylation, and product release) in the turnover process by these clinically important enzymes. The minimal inhibitory concentrations (MICs) 2The abbreviation used is: MICminimal inhibitory concentration. of β-lactam antibiotics were determined using the broth microdilution method, as recommended by the Clinical and Laboratory Standards Institute (19Clinical Institute Laboratory StandardsMethods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. 7th Ed. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania2006Google Scholar). GES-1, -2, and -5 were expressed in E. coli JM83 using the plasmids pHF:GES-1, pHF:GES-2, and pHF:GES-5, respectively. E. coli JM83 harboring pHF016 was used as a control. MICs were determined in Mueller-Hinton II broth (Difco) using a bacterial inoculum of 5 × 105 colony-forming units/ml. All plates were incubated at 37 °C for 16–20 h before results were interpreted. minimal inhibitory concentration. All spectrophotometric data were collected on a Cary 50 spectrophotometer (Varian) at 22 °C. Analyses were performed using the nonlinear regression program Prism 5 (GraphPad Software, Inc.) using data obtained from at least three independent experiments. Reactions containing 50 mm NaPi (pH 7.0), 100 mm NaCl, and varying concentrations of the β-lactam substrate were initiated by the addition of enzyme. The absorbance was monitored at the following wavelengths: imipenem (λ = 297 nm and Δϵ = −10,930 cm−1 m−1) and nitrocefin (λ = 500 nm and Δϵ = +15,900 cm−1 m−1). The steady-state velocities (v) were determined from the linear phase of the reaction time courses. The observed rate constants (kobs = v/[E]) were plotted as a function of the β-lactam concentration and fit non-linearly with the Michaelis-Menten equation to obtain the steady-state kinetic parameters kcat and Km. The parameters for nitrocefin hydrolysis by GES-1, -2, and -5 are given in supplemental Table 1. The substrate dissociation constant (Ks) for imipenem, with GES-1, -2, and -5, was determined by treating it as an inhibitor of nitrocefin hydrolysis as described previously (20Zafaralla G. Manavathu E.K. Lerner S.A. Mobashery S. Biochemistry. 1992; 31: 3847-3852Crossref PubMed Scopus (111) Google Scholar). Reactions containing 50 mm NaPi (pH 7.0), 100 mm NaCl, 160 μm (GES-1), 50 μm (GES-2), or 120 μm (GES-5) of nitrocefin, and varying concentrations of imipenem were initiated by the addition of the enzyme (200 pm final for GES-1 and GES-5 or 10 nm final for GES-2). The absorbance was monitored at 500 nm, and the steady-state velocities were determined from the linear phase of the reaction time courses. The steady-state velocity data were plotted as a function of imipenem concentration and fit with Equation 1. v=v0(1-(E+1+(Ks(1+SKm)))-(E+1+(Ks(1+SKm)))2-4EI2E)(Eq. 1) where v is the steady-state velocity, v0 is the steady-state velocity in the absence of imipenem, E is the enzyme concentration, I is the imipenem concentration, Ks is the dissociation constant for imipenem, S is the nitrocefin concentration, and Km is the Michaelis constant for nitrocefin hydrolysis. The dissociation constants for the product of imipenem hydrolysis (Ki,p) were determined as follows. Reactions containing 50 mm NaPi (pH 7.0), 100 mm NaCl, 160 μm (GES-1), 5 μm (GES-2), or 200 μm (GES-5) nitrocefin, and varying concentrations of hydrolyzed imipenem (up to 4 mm) were initiated by the addition of the enzyme (200 pm GES-1 and -5 or 10 nm GES-2 final). The absorbance was monitored at 500 nm, and the steady-state velocities were determined from the linear phase of the reaction time courses. The first-order rate constants describing acylation (k2) of GES-1, -2, and -5 by imipenem were determined under single turnover conditions. Reaction mixtures contained 50 mm NaPi (pH 7.0), 100 mm NaCl, 75 μm enzyme, and 15 μm imipenem. Acylation was detected by monitoring the opening of the β-lactam ring of imipenem at 297 nm (Δϵ297 = −10,930 cm−1 m−1) with the aid of an SFA-20 stopped-flow apparatus (Hi-Tech Scientific, Salisbury, UK), and the time courses were fit with Equation 2. At=(A0-A∞)e-k2t+A∞(Eq. 2) where At is the absorbance at time t, A0 is the initial absorbance, A∞ is the final absorbance, and k2 is the observed first-order rate constant for enzyme acylation. Acylation of GES-5 by imipenem under single turnover conditions resulted in two distinct exponential phases, which was fit with Equation 3. At=(A0-A∞)(Ffast)e-kfastt+(A0-A∞)(1-Ffast)e-kslowt+A∞(Eq. 3) where At, A0, and A∞ are as defined in Equation 2, Ffast is the fraction of the reaction corresponding to the fast phase, kfast is the observed first-order rate constant for the fast phase, and kslow is the observed first-order rate constant for the slow phase. The rate at which imipenem was displaced from the active site of GES-1, -2, and -5 was determined as described previously (21Taibi P. Mobashery S. J. Am. Chem. Soc. 1995; 117: 7600-7605Crossref Scopus (53) Google Scholar). Briefly, a reaction containing 50 mm NaPi (pH 7.0), 100 mm NaCl, and 1 μm GES-1 and -2 or 750 nm GES-5 in the absence and presence of 20 μm (in the case of GES-1), 5 μm (in the case of GES-2), or 15 μm (in the case of GES-5) imipenem (10 × Km) was incubated at room for This reaction was and/or a reaction containing 50 mm NaPi (pH 7.0), 100 mm NaCl, and μm (in the case of GES-1), 50 μm (in the case of GES-2), or μm (in the case of GES-5) of nitrocefin, and nitrocefin hydrolysis was monitored at 500 The rate constant describing of activity was determined by the absorbance time data with Equation where At is the absorbance at time t, A0 is the initial absorbance, is the steady-state velocity, and is the rate constant for the of activity of imipenem by GES-1, -2, and -5 be described by 1. The following kinetic parameters be for 1. The for and for GES-1, -2, and -5 and the for for GES-5 were using and the determined for and/or We a to the MICs of β-lactam antibiotics by GES enzymes under an in E. coli the results of Table 1 supplemental Table 2) the breadth of activity for all three enzymes is All are to including the and and The of GES-1 and -2 resistance to the third-generation cephalosporins is the case with but the that the enzyme has resistance to is the in resistance carbapenems and by GES-5 We that the MICs for carbapenems within a E. coli for imipenem with GES-5) are considered However, the of variants such as GES-5 in combination with of carbapenem such as the of results in resistance to carbapenems in clinical P. Poirel L. Clin. Microbiol. Infect. 2002; 8: 321-331Abstract Full Text Full Text PDF PubMed Scopus (595) Google Scholar, Kim Lee K. Diagn. Microbiol. Infect. Dis. 2007; PubMed Scopus Google Scholar). These in the of the residue at position 170 in the substrate of these of carbapenem antibiotics for E. coli JM83 GES E. coli JM83 harboring the pHF016 containing no β-lactamase E. coli JM83 harboring the pHF016 containing no β-lactamase in a The GES-1, -2, and -5 enzymes were to for kinetic Class A β-lactamases GES are by β-lactam antibiotics at a step that is by S.O. J.F. Mobashery S. J. Am. Chem. Soc. 2005; PubMed Scopus Google Scholar). and residue that in GES-1, -2, and the within the active This deacylation of the to substrate We the kinetics of imipenem turnover in of imipenem by GES-1 and -2 was compared with the case of The significant on steady-state parameters is on in a two of in kcat/Km for hydrolysis of imipenem from GES-1 to for substrate turnover by Km) is at but enzyme acylation was to of the dissociation constants for the The Ks for imipenem was 10 nm for GES-1 but for GES-2 and -5, it was in the The for Km is the Ks for each GES This that acylation (k2) is dissociation of the substrate from the to is for following Michaelis-Menten kinetics A. and in A to and parameters for hydrolysis of imipenem by GES 1) × 1) × × × × × × × × under single turnover conditions resulted in The phase acylation under turnover Acylation under single turnover conditions resulted in The phase acylation under turnover conditions. in a We also determined the microscopic rate constant (k2) for acylation of GES-1, -2, and -5 by imipenem and supplemental The acylation rate constant (k2) was for GES-1 and -2 and was to kcat in the case of GES-1, that acylation is the rate-determining step in imipenem hydrolysis by this enzyme. This was as the deacylation step has been to be in the turnover of carbapenems by class A enzymes for which the has been L. K. P. A. Mobashery S. J. Am. Chem. Soc. Scopus Google Scholar). The time for acylation of GES-5 not a single exponential time revealed that an initial phase for one of the turnover = followed by a phase = We that imipenem in as a distinct of two of 2) that 1) L. J. J. Chem. Scopus Google Scholar). is that GES-5 the two the E rapidly the steady-state GES-5 would both However, the would hydrolysis of the E from a kinetic to the in the acylation rate constants for the two This is also by the that the kcat is the rate constant describing the phase. two distinct enzyme that acylation by imipenem with rate We that the phase acylation of GES-5 under steady-state conditions and that the acylation rate constant is kcat and is not for this enzyme This a remarkable and enhancement of the rate of acylation of the GES-5 enzyme over that of GES-1 and -2, by imipenem. We the deacylation rate constant for the turnover of imipenem by monitoring of enzyme activity and supplemental 2) (21Taibi P. Mobashery S. J. Am. Chem. Soc. 1995; 117: 7600-7605Crossref Scopus (53) Google Scholar). We that we the product of imipenem hydrolysis and of and 1) by of this product with the GES variants revealed the dissociation of the is 4 mm) and would not the of The GES-1 experiences deacylation with a rate constant of that acylation by imipenem is for this enzyme. The GES-2 deacylation with a rate constant of to the for the acylation which that acylation deacylation is for this The of by this is which is the of kcat for hydrolysis of imipenem by we were to for GES-5 by this method, the for this rate constant be using Equation 5 and for kcat and k2 The deacylation rate constant for GES-5 is to and k2 is that this step is in contrast to the of GES-1 and The GES-5 has a enhancement in the deacylation rate over that of GES-1 and -2, which is for the manifestation of imipenem the that the of the enhancement for the acylation step is it is for deacylation, it would that the enhanced rate of acylation in with the in are the critical for the of carbapenemase resistance in of microscopic rate constants for substrate and substrate are not these rate constants were using data and The GES-1 containing at position has the for imipenem to a rate constant for substrate is to that each substitution at position from to and -2, and -5, results in in the rate constant for imipenem and a in the rate constants for imipenem This to a for imipenem from GES-1 to GES-2 to This is for an enzyme that a as the of for the substrate the of substrate of the of GES-1 and carbapenemases to class A β-lactamases, which do not hydrolyze carbapenems, in their active The x-ray structure only a of the enzyme, in the structure in which its ability to hydrolyze carbapenem antibiotics. The Ω-loop which both for and in class A enzymes 2) at least in the case of a of the TEM it has been to be a P. M. I. Lerner S.A. Mobashery S. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, P. I. Vakulenko Lerner S.A. Mobashery S. J. Am. Chem. Soc. Scopus (33) Google Scholar, T. Le M. H. Microbiol. PubMed Scopus Google Scholar). Both and β-lactamases are to carbapenems; however, only is to turn We have previously that of the Ω-loop in hydrolysis of carbapenems L. K. P. A. Mobashery S. J. Am. Chem. Soc. Scopus Google Scholar). We the Ω-loop within the active site of GES-1 is a this at least GES-1 and hydrolyze carbapenems. this be critical for the GES-5 enzyme, as it has an enhanced rate of deacylation for imipenem. A revealed in the Ω-loop the active site at least by The also revealed the of a and within the active site of GES-1, the deacylation This that as in the case of of the Ω-loop enzyme deacylation. A single amino acid substitution at position 170 of GES enzymes has a on the turnover of the carbapenem antibiotic imipenem. The GES-1 enzyme with has a for imipenem but is to turn it over to the rate constants for acylation and deacylation. to in results in the canonical residue at this position for class A β-lactamases. This no in the rate constant for deacylation, but the rate constant for acylation is enhanced such that is The GES-5 enzyme, with an enhancement of both microscopic rate however, the in the kinetic profile of GES-5 is the and in the rate constant for acylation over that of GES-1 and respectively. This results in the of the rate-determining step of the reaction from acylation to deacylation and that the enhanced rate of deacylation is for the increased resistance to imipenem. is not at the from a structural why the residue at position 170 have an on the rate of acylation and/or deacylation. of these the of x-ray for the of these enzymes with carbapenem antibiotics.
22
Laurent Poirel, Isabelle Thomas, Thierry Naas et al. · Antimicrobial Agents and Chemotherapy · 2000 · 418 citations · Full text
Samy O. Meroueh, Jed F. Fisher, H. Bernhard Schlegel et al. · Journal of the American Chemical Society · 2005 · 156 citations